Peijia Medical Limited (9996.HK) Income Statement Analysis – Financial Results

About Peijia Medical Limited

Peijia Medical Limited engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices. Its transcatheter valve therapeutic products include TaurusOne, a transcatheter aortic valve replacement (TAVR) system; TaurusElite, a retrievable TAVR system; TaurusNXT, a non-glutaraldehyde crosslinking dry-tissue TAVR system; TaurusWave, a lithotripsy valvuloplasty system; TaurusApex, a polymer leaflets TAVR system; Trilogy, a TAVR System; HighLife, a transseptal mitral value replacement system; SpyderOne, a transapical transcatheter mitral valve replacement (TMVR) system; Sutra, a TMV coaptation augmentation system; GeminiOne, a transcatheter edge-to-edge repair system; MonarQ and Peijia, which are transcatheter tricuspid valve replacement systems; TaurusAtlas, a transfemoral ballon catheter; TaurusExplora, a pre-shaped guidewire; and introducer sheath. The company also offers Jasper and Presgo, that are detachable coils; Jasper SS detachable coil; intracranial adjunctive stents; SacSpeed, a balloon dilatation catheter; Tethys AS, an aspiration catheter; Syphonet, a stent retriever; Neway, a balloon microcatheter; Fluxcap, a balloon guiding catheter; NeuroStellar, an intracranial stent; Presgo microcatheter and micro guidewire; Heralder guiding catheter and distal access catheter; Tethys, an intermediate catheter; and Jasper power supply. In addition, it engages in the trading business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.